• OFID 2018:5 (Suppl 1) • Oral Abstracts no approved vaccines and only one moderately effective marketed antibody (Synagis®) for the prevention of RSV infection in high-risk infants. Sampling the human antibody repertoire has led to the realization that the RSV fusion (F) protein in its prefusion conformation is the preferred target for potent neutralizing antibodies and thus makes the protein an attractive candidate for vaccine developers.
Exploring Clinical and Antiviral Efficacy of Baloxavir Marboxil in a
Background. Baloxavir marboxil (BXM), a selective cap-dependent endonuclease inhibitor, has demonstrated efficacy + safety for influenza in otherwise healthy patients. We present subgroup analyses for (i) United States vs. Japan (J), (ii) time (t) of treatment (early: ≥0 to ≤24 hours, vs. late: >24 to ≤48 hours), and (iii) influenza type B infections from the global Ph 3 trial (16/17 season).
Methods. A multicenter, randomized, double-blind, placebo (PLC)-and oseltamivir (OV)-controlled study recruited patients in Japan (n = 846) and United States (n = 590). Inclusion criteria: age 12-64 years, fever + flu symptoms, and ≤48 hours from symptom onset. Patients (20-64 years) randomized (2:2:1) to a single oral dose of BXM, PLC, or 75 mg OV BID for 5 days; patients 12-19 years were randomized (2:1) to receive BXM or PLC. BXM dose: 40/80 mg for BW </≥80 kg. Primary endpoint: time to alleviation of symptoms (TTAS) in ITTI population (pop). Viral titers measured from pre-/postdose nasal swabs.
Results. BXM reduced the median TTAS by 30.6 hours versus PLC (87.3 versus 117.9 hours, P = 0.1373) in the US pop and t to cessation of viral shedding: 24 versus 72 hours for PLC (P < .0001). Median TTAS in the United States versus J pop was longer, due to imbalances between groups. In both early/late treatments from symptom onset, BXM reduced TTAS versus PLC (Table 1) . Regardless of the t to treatment from symptom onset, BXM reduced virus titer significantly from BL versus PLC and OV ( Methods. RSV RNA was isolated from nasal swabs collected at baseline and postbaseline in studies GS-US-218-0108, GS-US-218-1502, GS-US-218-1227, and GS-US-218-1797. Full-length RSV fusion (F) gene was PCR amplified and population sequencing was performed.
Combined Resistance Analyses From Phase 2b Studies of Presatovir Treatment in RSV-Infected Adults
Results. Of 233 presatovir-treated adults in the efficacy analyses, post-baseline resistance-associated substitutions were detected in 18 (7.7%) subjects. Frequencies of resistance development varied by study (Table 1) . Resistance substitutions known to confer high-level (>200 fold) reduced susceptibility to presatovir detected in >1 subject were: T400I (n = 6), S398L (n = 3), L141F (n = 2), and F140I (n = 2) in F. Subjects with resistant virus had less viral load reduction than presatovir-treated subjects without resistant virus. Resistance development did not impact clinical outcomes. In study GS-US-218-0108, subjects with lymphopenia (<200 cells/μL) at baseline were significantly more likely to develop resistance substitutions. Conclusion. Presatovir treatment resulted in varying rates of resistance development across 4 phase 2b studies. Resistance development impacted virologic response without affecting clinical outcomes. Differences among study populations and dosing regimens may have influenced rates of resistance development.
